FDA Adds Boxed Warning to CAR T-Cell Therapies, but Says Benefits Outweigh Risks of Secondary Cancers
Melissa Suran
Abstract
This Medical News article discusses the US Food and Drug Administration’s new boxed warning requirement and investigation of secondary malignancies after CAR T-cell therapy.
Topics & Concepts
MedicineFood and drug administrationDrug approvalIntensive care medicineDrugMedical emergencyPharmacologyBiomedical Ethics and RegulationScience, Research, and MedicinePharmaceutical Economics and Policy